Interferon-Beta Increases Plasma Ceramides of Specific Chain Length in Multiple Sclerosis Patients, Unlike Fingolimod or Natalizumab

Fingolimod is used for the treatment of multiple sclerosis (MS) and targets receptors for the bioactive sphingolipid sphingosine-1-phosphate (S1P). Whether fingolimod or other MS therapies conversely affect plasma concentrations of sphingolipids has, however, not yet been analyzed. Herein, we quanti...

Descripción completa

Detalles Bibliográficos
Autores principales: Ottenlinger, Florian M., Mayer, Christoph A., Ferreirós, Nerea, Schreiber, Yannick, Schwiebs, Anja, Schmidt, Katrin G., Ackermann, Hanns, Pfeilschifter, Josef M., Radeke, Heinfried H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2016
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5093125/
https://www.ncbi.nlm.nih.gov/pubmed/27857690
http://dx.doi.org/10.3389/fphar.2016.00412

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5093125/
https://www.ncbi.nlm.nih.gov/pubmed/27857690
http://dx.doi.org/10.3389/fphar.2016.00412

Ejemplares similares